Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion
-
Published:2024-01-27
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Pallavi RaniORCID, Gatti Elena, Durfort TiphanieORCID, Stendardo Massimo, Ravasio RobertoORCID, Leonardi TommasoORCID, Falvo Paolo, Duso Bruno AchuttiORCID, Punzi Simona, Xieraili Aobuli, Polazzi Andrea, Verrelli DorianaORCID, Trastulli DeborahORCID, Ronzoni Simona, Frascolla Simone, Perticari GiuliaORCID, Elgendy Mohamed, Varasi Mario, Colombo EmanuelaORCID, Giorgio Marco, Lanfrancone LuisaORCID, Minucci Saverio, Mazzarella LucaORCID, Pelicci Pier GiuseppeORCID
Abstract
AbstractCaloric Restriction (CR) has established anti-cancer effects, but its clinical relevance and molecular mechanism remain largely undefined. Here, we investigate CR’s impact on several mouse models of Acute Myeloid Leukemias, including Acute Promyelocytic Leukemia, a subtype strongly affected by obesity. After an initial marked anti-tumor effect, lethal disease invariably re-emerges. Initially, CR leads to cell-cycle restriction, apoptosis, and inhibition of TOR and insulin/IGF1 signaling. The relapse, instead, is associated with the non-genetic selection of Leukemia Initiating Cells and the downregulation of double-stranded RNA (dsRNA) sensing and Interferon (IFN) signaling genes. The CR-induced adaptive phenotype is highly sensitive to pharmacological or genetic ablation of LSD1, a lysine demethylase regulating both stem cells and dsRNA/ IFN signaling. CR + LSD1 inhibition leads to the re-activation of dsRNA/IFN signaling, massive RNASEL-dependent apoptosis, and complete leukemia eradication in ~90% of mice. Importantly, CR-LSD1 interaction can be modeled in vivo and in vitro by combining LSD1 ablation with pharmacological inhibitors of insulin/IGF1 or dual PI3K/MEK blockade. Mechanistically, insulin/IGF1 inhibition sensitizes blasts to LSD1-induced death by inhibiting the anti-apoptotic factor CFLAR. CR and LSD1 inhibition also synergize in patient-derived AML and triple-negative breast cancer xenografts. Our data provide a rationale for epi-metabolic pharmacologic combinations across multiple tumors.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference87 articles.
1. O’Flanagan, C. H., Smith, L. A., McDonell, S. B. & Hursting, S. D. When less may be more: Calorie restriction and response to cancer therapy. BMC Med 15, 106 (2017). 2. Nencioni, A., Caffa, I., Cortellino, S. & Longo, V. D. Fasting and cancer: molecular mechanisms and clinical application. Nat Rev Cancer 18, 707–719 (2018). 3. Ibrahim, E. M., Al-Foheidi, M. H. & Al-Mansour, M. M. Energy and caloric restriction, and fasting and cancer: a narrative review. Supportive Care Cancer 29, 2299–2304, (2021). 4. García-Jiménez, C. & Goding, C. R. Starvation and Pseudo-Starvation as Drivers of Cancer Metastasis through Translation Reprogramming. Cell Metabolism 29 254–267, (2019). 5. Kalaany, N. Y. & Sabatini, D. M. Tumours with PI3K activation are resistant to dietary restriction. Nature 458, 725–731 (2009).
|
|